Bayeng Fuyang, Pfizer's new crown oral medicine?

The news of the US President Biden's new crown Fuyang swipes the screen social media.

American White House President Kevin Oakna said on July 30, local time that the results of the new crown virus test on the day of President Biden were positive again. On the 27th, the test results of Biden's new crown virus were just negative, and then wasolate.

Why did Bayon appear in just a few days?

Looking back at Biden's entire treatment process, he was diagnosed on July 21 to diagnose the infection with the infection of the new crown virus, and there were symptoms such as runny nose, throat pain, fatigue and other symptoms. The We/Litonovy combination also completed the 5 -day new crown antiviral drug Paxlovid.

In a memorandum of the White House said that after Biden's reunion, he did not have symptoms and good feelings. At present, he does not need to restore treatment, but you need to continue observation and re -enter the isolation. Aconner said a small number of people who took Neymarrtova/Litnaville's new crown patients appeared positive for re -examination.

Anti -Virus oral drug Nametovir/Lotnavid (Paxlovid) is a new crown oral medication developed by Pfizer, a US pharmaceutical company. In December 2021, the drug was obtained by the U.S. Food and Drug Administration (FDA). It is suitable for adult patients with mild to moderate new crown pneumonia (COVID-19) and adult patients with direct detection results by SARS-COV-2 virus and potentially intensive (including hospitalization or death) risk factors. Phaxlovid is the first newly -authorized new crown oral drug in the United States and was used in December 2021.

In the first half of this year, Pfizer's Paxlovid sales anti -Molnupiravir, Molnupiravir, who surpassed Murisha, reached $ 9.6 billion. Since the first quarter of 2022, PAXLOVID's prescription in the United States has increased by nearly 5 times, and it has continued to occupy more than 90%of the market share in the US market.

It is worth noting that after taking Phaxlovid, the new crown infected person has happened for the first time.

Earlier, He Dayi, a 70 -year -old Chinese medical scientist, a 70 -year -old AIDS scholar, and Anthony Fitch, director of the National Institute of Allergies and Infectious Diseases, also appeared after taking Paxlovid.

After taking a standard treatment (5 days) Phae antiviral drug Paxlovid, Fudi experienced a rebound of symptoms. In the case, he said that he was tested again after being positive and became worse. "When the symptoms appear, I started to feel very bad, worse than the first time." He said. Based on the symptoms of Foic, the doctor gave him another course of PAXLOVID antiviral drugs.

PaxLovid belongs to a 3CL protease inhibitor. It is a small molecular drug and a new crown therapeutic drug that is currently recognized. At present, many companies around the world are also developing similar new crown 3CL protease inhibitors. Today, PAXLovid has repeatedly appeared "rollover", does it mean that the efficacy of the medicine is failing?

A small study of nearly 500 high -risk patients in June showed that the average new crown patients with an average of less than 1%of the new crown patients rebounded in about 9 days after taking PaxLovid; In scale research, 6%of patients rebounded within one month after treatment.

Experts from Pfizer Pharmaceutical Company have said that during the clinical experimental stage of the drug, some patients have observed the phenomenon of virus rebounds, but they have this phenomenon in the drug treatment group and placebo group, and the proportion of the two groups is equivalent. About 1%-2%, indicating that the patient's virus rebound has nothing to do with treatment drugs.

Some new crown therapy experts told the First Financial reporter that the Fuyang problem of Paxlovid may still be related to the treatment of the original design of the medicine, and it may not be enough to take 5 days.

It is worth mentioning that PaxLovid is currently obtained by emergency use, which is based on the clinical trial solution designed by the Delta epidemic. Nowadays, no matter in the United States or the new crown virus in other countries, it has been replaced by Omikon, and the characteristics of the two viruses have changed a lot, such as the latter's contagiousness is much greater than the former.

There are also new crown drug developers told the first financial reporter that after taking Paxlovid, why the problem of rehabilitation occurred is currently not very clear from scientifically, but it may not be related to the drug. "Anti -virus drugs cannot kill the virus, but only block virus replication. Some documents reported that the virus RNA fragments could be left in the intestinal tract after recovery. In words, the level that the virus is inhibited to low to modern conventional detection technology is not necessarily absolutely clear. For example, in AIDS treatment, when antiviral therapy drugs are used, the virus replication is inhibited. After a period of treatment, it usually takes several months for AIDS treatment. The virus is inhibited to low to the level that is not detected by modern conventional testing technology, but after stopping treatment for a period of time, the virus rebounds again. The problem of virus rebound after antiviral drugs is also related to the performance of the virus, which needs to be observed. "And Fitch once emphasized that the purpose of PaxLovid is" let you stay away from the hospital and prevent you from developing a serious disease. " According to data from the US CDC last month, even those who rebounded in the symptoms caused a very low proportion of severe results. Data show that within 5 to 15 days after stopping the medicine, less than 1%of patients were admitted to the hospital due to their symptoms.

An Israeli study conducted by Israel this winter shows that PAXLOVID has no significant effect on the hospitalization rate of patients with risk factors under vaccine under 65 years of age. Experts believe that if people who can be young and vaccinated prove the necessity of using this drug, it will be more convincing.

Some experts have suggested that in order to avoid the possibility of small molecular drugs to produce drug resistance, it is necessary to test other drugs and develop cocktail therapy, which is expected to eliminate the possible new crown rebound.

- END -